⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909130 | 0.73 | — | — | |
| SCHEMBL114603 | 0.73 | — | — | |
| SCHEMBL1132279 | 0.72 | — | — | |
| SCHEMBL138565 | 0.71 | — | — | |
| SCHEMBL1162842 | 0.69 | — | — | |
| SCHEMBL1673128 | 0.68 | — | — | |
| SCHEMBL451027 | 0.68 | KDM4C (0.34) | — | |
| SCHEMBL1925074 | 0.68 | GOT1 (0.33) | — | |
| SCHEMBL155358 | 0.68 | KDM4E (0.52) | — | |
| SCHEMBL14248975 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035622-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC (US) | 2024-02-15 | — | — | WO | claimed |
| CN-110734418-B | Condensed-cyclic compound, composition including the same, and organic light-emitting device | 三星电子株式会社 | 2024-01-26 | — | — | CN | claimed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | claimed |
| EP-4028388-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-20 | — | — | EP | claimed |
| CN-114728912-A | MTA-synergistic PRMT5 inhibitors | 米拉蒂医疗股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | claimed |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | claimed |
| WO-2021050915-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-18 | — | — | WO | claimed |
| CN-111362920-A | Compound as IRAK inhibitor | 上海美悦生物科技发展有限公司 | 2020-07-03 | — | — | CN | claimed |
| US-10683263-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2020-06-16 | — | — | US | claimed |
| US-20070184979-A1 | Novel sulfonylpyrroles | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| EP-1517895-B1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2007-03-14 | — | — | EP | claimed |
| CN-1926103-A | Sulfonyl pyrroles as HDAC inhibitors | ALTANA PHARMA AG (DE) | 2007-03-07 | — | — | CN | claimed |
| US-7153968-B2 | 8-(biaryl)quinoline PDE4 inhibitors | MERCK FROSST CANADA, LTD. (CA) | 2006-12-26 | — | — | US | claimed |
| EP-1725528-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | claimed |
| US-20050234238-A1 | 8-(Biaryl)quinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-10-20 | — | — | US | claimed |
| WO-2005087724-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | claimed |
| EP-1517895-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-03-30 | — | — | EP | claimed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | claimed |
| WO-2004000814-A1 | 8-(BIARYL) QUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-12-31 | — | — | WO | claimed |